skip to the content

Science of VEGF

Angiogenesis is essential to tumour development and a key mediator of this process is the continuously expressed VEGF.1–3 Precise VEGF inhibition helps maintain control of tumour-induced angiogenesis and thus control of tumour growth and metastases.

 

Precise VEGF inhibition has been clinically proven to provide significant benefit when used in combination with major conventional cancer regimens and several clinical trials demonstrate benefit of precise VEGF inhibition in multiple tumour types.4–8

 

This section provides a detailed review of angiogenesis and its predominant mediator, VEGF, discusses the rationale for precise and continuous VEGF inhibition as an antitumour strategy and considers the role of angiogenesis across a number of different tumour types.






 

References

  1. Folkman J. In: DeVita VT Jr, Hellmann SMD, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005. p. 2865–82.
  2. Willett CG, Boucher Y, di Tomaso E, et al. Nat Med 2004;10:145–7.
  3. Avastin Summary of Product Characteristics. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/emea-combined-h582en.pdf
  4. Hurwitz H, Fehrenbacher L, Novotny W, et al. N Engl J Med 2004;350:2335–42.
  5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. J Clin Oncol 2007;25:1539–44.
  6. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. J Clin Oncol 2009;27:4966–72.
  7. Sandler A, Gray R, Perry MC, et al. N Engl J Med 2006;355:2542–50.
  8. Escudier B, Pluzanska A, Koralewski P, et al. Lancet 2007;370:2103–11.

Proposed MoA of anti-VEGF agents

Proposed MoA
of anti-VEGF
agents.
Learn more.

Strategies for inhibiting

Strategies for
inhibiting the
VEGF pathway.
Learn more.

Landmark papers

Landmark papers in
VEGF research.
Learn more.